Cardiomedex

#ESCcongress 2024 is less than one week away, and I can’t wait to see you in London on August 30th-September 2nd ! Stop by the moderated poster session ”HFpEF: data from animal studies and registries” on Sunday, September 1st, from 8-8:50 am at Station 2-Research Gateway On behalf of our people at Cardiomedex , I am very excited to be presenting our latest HFpEF model, the SDT fatty rat developed in collaboration with our privileged partners Physiogenex and CLEA Japan, Inc. . This type 2 diabetic model is a very promising model to translate the hypertension/kidney dysfunction and cardiometabolic clinical HFpEF phenogroups and is a relevant model to evaluate drugs targeting HFpEF.   If you are attending #ESCcongress 2024, I would love to connect and share ideas. Otherwise, contact us online to set-up an appointment and/or discuss your drug development projects with us: https://lnkd.in/eWkX9McT #ESCcongress 2024 #heartfailure #cardiovascular #HFpEF #diabetes #cardiorenal #Hypertension #Obesity #preclinical #innovation Caroline Dubroca Aurélie Waget François Briand MASAMI SHINOHARA, PhD Yasushi Kageyama Thierry Sulpice

Cardiomedex, a proud sponsor of the 3rd Heart Failure Drug Discovery & Development Summit taking place in Boston on July 30 and August 1, 2024 Drug development for heart failure with preserved ejection fraction (HFpEF) is partly hampered by a lack of appropriate pre-clinical models with a translational value, given the complexity of the pathophysiology of this disease and the co-existence of comorbidities in patients. No model will capture all human HFpEF variables. …. That is why at Cardiomedex, in collaboration with our subsidiary company Physiogenex, we developed several models each capturing specific human HFpEF features. 🗣 Come and join us on Wednesday 31st of July at 11:45 am for our presentation session entitled “ One model does not fit all : The search for relevant rodent models to feature the different phenogroups of heart failure with preserved ejection fraction.   🗒 Then join us during the scientific poster session to learn more about our phenogroups targeted preclinical models. 🎯 I will be glad to discuss and share ideas about the development of translational preclinical models to help finding new treatments for patients suffering from heart failure. See you on Wednesday!

Olà! Heading to Lisbon this Saturday to attend the ESC heart failure annual meeting? Stop by the moderated poster session” Chronic heart failure - pathophysiology and mechanisms 12” on Saturday 11th of May from 16:00-16:15 (poster #60389). On behalf of our people at Cardiomedex, I am very excited to be presenting 3 of our clinically relevant preclinical HFpEF models. One model does not fit all…. That is why at Cardiomedex, in collaboration with our subsidiary company Physiogenex, we developed several models each capturing specific human HFpEF features. The Diet-Induced Obese NASH Hamster, The Angiotensin-Infused Mouse and The High Fat Diet+L-NAME Mouse are 3 translational rodent models embracing the complex pathophysiology of HFpEF. These preclinical models provide a unique opportunity to evaluate the efficacy of drugs targeting specific phenogroups of HFpEF.     If you are attending #HeartFailure2024, I would love to connect and share ideas. Otherwise, contact us online to set-up an appointment and/or discuss your drug development projects with us: https://lnkd.in/eWkX9McT #HFA_ESC #heartfailure #cardiovascular #heart_failure #HFpEF #MASH #Hypertension #Obesity #preclinical #innovation   Thierry Sulpice Caroline Dubroca François Briand Yosra Doghri Kévin Perrier

Congratulations to Patrick de Boer and the Aiosyn team as they announce their new partnership with Physiogenex to advance kidney disease drug development. 🔬 Working together, the two companies will drive forward Chronic Kidney Disease (CKD) drug development through the combination of Aiosyn’s #AI-powered NephroPath platform and the preclinical models and research capabilities of Physiogenex. “The Aiosyn NephroPath platform now provides a wonderful tool to better quantify kidney lesions in our animal models of CKD. This new AI-powered imaging technology delivers a greater sensitivity to detect the drugs’ efficacy. Keeping in mind the translational aspect of Aiosyn’s NephroPath, this will help our clients to expedite their development programs towards the clinics,” said Dr. Thierry Sulpice, CEO/CSO of Physiogenex. For more information on this partnership, click here: https://lnkd.in/evkGEkeg Andy, Sven, Dagmar, Sabine, Thomas, Meron, Federico, Pim, Henk, Jorge #innovation #startup #goodthingsarecoming #aiinpathology

Cardiomedex team is growing and recruits ! Join us #hiring #cardiovascular #echocardiography #preclinical

Cardiomedex team is growing and recruits ! Join us #hiring #cardiovascular #echocardiography #preclinical

Cardiomedex team is growing and recruits ! Join us #hiring #cardiovascular #echocardiography #preclinical

Goodbye Philly! I am thrilled to have had the opportunity to attend the #AHA23 scientific sessions these past days ! I had the privilege to hearing passionate individuals and engaging insightful discussions about the latest findings in the cardiovascular science.   Thank you for the inspiring discussions around our model of severe heart failure with preserved ejection fraction (HFpEF) related to liver fibrosis/NASH and alterations in kidney function. At Cardiomedex and Physiogenex , we are committed to improve patients’ live suffering from cardiovascular and cardiometabolic diseases and will continue to develop innovative solutions to support preclinical development of new therapeutic options for these patients. Keep up the good work Cardiomedex and Physiogenex teams. Reach out to learn more about this preclinical model and the unique opportunity to evaluate the efficacy of drugs targeting HFpEF https://lnkd.in/eWkX9McT #cardiovascular #heat_failure #HFpEF #myocardial_infarction #ischemia_reperfusion #hypertension #diabetes #cardiotoxicity #sepsis #cardiorenal #cardiometabolic #efficacy #safety #teamwork #innovation